Modulation of lipid metabolism gene

The term "Modulation of lipid metabolism gene" refers to a broad pharmacological or biological process rather than a specific, discrete therapeutic target like a single protein or receptor. It encompasses the regulatory changes in the expression of various genes that control the synthesis, transport, and breakdown of lipids, including enzymes like Fatty Acid Synthase (FASN) and lipases such as Hormone-Sensitive Lipase (HSL) [2, 6]. This modulation is typically achieved through the interaction of drugs or bioactive compounds with upstream transcription factors, such as Peroxisome Proliferator-Activated Receptors (PPARs), Sterol Regulatory Element-Binding Proteins (SREBPs), or Liver X Receptors (LXRs), and signaling pathways like AMPK and PI3K/Akt [1, 3]. Because it describes a systemic functional effect rather than a singular molecular entity, it is categorized as a pathway-level intervention or mechanism of action [1, 10]. Therapeutic strategies aimed at this process are primarily explored for treating metabolic disorders, including obesity, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease [8, 9]. However, the multi-target nature of such modulation poses challenges for drug development, particularly regarding tissue specificity and potential off-target effects [1, 4].

Other names

Regulation of lipid metabolism genesLipid metabolism gene expression modulationTranscriptional control of lipid metabolism

Drugs typically alter the transcriptional activity of gene networks involved in lipid handling by activating or inhibiting transcription factors (e.g., PPARs, SREBPs) or metabolic sensors (e.g., AMPK), thereby increasing fatty acid oxidation and decreasing lipogenesis.